Cargando...

A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia

FMS-like tyrosine kinase 3 (FLT3) tyrosine kinase inhibitors (TKIs) have activity in acute myeloid leukemia (AML) patients with FLT3 internal tandem duplication (ITD) mutations, but efficacy is limited by resistance-conferring kinase domain mutations. This phase 1/2 study evaluated the safety, toler...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: Smith, Catherine C., Levis, Mark J., Frankfurt, Olga, Pagel, John M., Roboz, Gail J., Stone, Richard M., Wang, Eunice S., Severson, Paul L., West, Brian L., Le, Mai H., Kayser, Sabine, Lam, Bao, Hsu, Henry H., Zhang, Chao, Bollag, Gideon, Perl, Alexander E.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2020
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7189289/
https://ncbi.nlm.nih.gov/pubmed/32330242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001449
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!